ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
3,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
4,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
6,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
7,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
9,2,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
9,3,Vulvovaginal burning sensation,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
10,1,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
10,2,Headache,Headaches NEC,Headaches,Nerv,N
10,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,1,Deafness,Hearing losses,Hearing disorders,Ear,N
12,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
13,1,Otitis externa,Ear infections,Infections - pathogen unspecified,Infec,N
14,1,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
14,2,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
15,1,Otitis externa,Ear infections,Infections - pathogen unspecified,Infec,N
16,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
16,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
17,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
17,2,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
18,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
19,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
19,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
19,3,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
20,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
20,2,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
20,3,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
20,4,Application site rash,Application site reactions,Administration site reactions,Genrl,N
20,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
20,6,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
21,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
21,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
21,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
21,4,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
21,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
22,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
23,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
24,1,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
24,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
25,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
25,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
25,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
26,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
27,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
28,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
28,2,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
28,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
29,1,Product caught fire,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
30,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
31,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
31,2,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
32,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
33,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
33,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
33,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
34,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
35,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
35,2,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
35,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
36,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
36,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
37,1,Hair texture abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
37,2,Hair texture abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
38,1,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
39,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
39,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
40,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
40,2,Eczema weeping,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
41,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
